Abstract
Purpose
To compare the efficacy of the oral dienogest versus triptorelin acetate injection for treatment of premenopausal menorrhagia and pelvic pains in women with uterine adenomyosis.
Methods
A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited. First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks. Outpatient follow-up was undertaken after 8 weeks but mean values were calculated at baseline and after 16 weeks (end of treatment).
Results
A total of 41 women were allocated to treatment with dienogest (n = 22) or triptorelin acetate (n = 19); 19 (86.4 %) and 18 (94.7 %) % of the respective groups completed the trial. Significant reductions in pelvic pains after 16 weeks treatment were obtained in both groups demonstrating the equivalence of dienogest relative to triptorelin acetate. Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.
Conclusions
Dienogest may be a valuable alternative to depot triptorelin acetate for treatment of premenopausal pelvic pains in women with uterine adenomyosis.
Similar content being viewed by others
References
Wang PH, Su WH, Sheu BC, Liu WM (2009) Adenomyosis and its variance: adenomyoma and female fertility. Taiwan J Obstet Gynecol 48:232–238
Kitawaki J (2006) Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 20:493–502
Wood C (2001) Adenomyosis: difficult to diagnose, and difficult to treat. Diagn Ther Endosc 7:89–95
Kitamura Y, Allison SJ, Jha RC, Spies JB, Flick PA, Ascher SM (2006) MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol 186:855–864
Sheng J, Zhang WY, Zhang JP, Lu D (2009) The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 79:18993
Nelson JR, Corson SL (1993) Long-term management of adeno-myosis with a gonadotropin-releasing hormone agonist: a case report. Fertil Steril 59:441–443
Ahmed B, Aboubakr E, Alaa M (2012) Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 91:489–495
Oettel M, Breitbarth H, Elger W et al (1999) The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 4:2–13
Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 108(1):21–25
Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Sørensen JS, Olesen F (2001) Magnetic resonance imaging and transvaginal ultrasonography for diagnosis of adenomyosis. Fertil Steril 76:588–594
Nishida M, Takano K, Arai Y, Ozone H, Ichikawa R (2010) Conservative surgical management for diffuse uterine adenomyosis. Fertil Steril 94(2):715–719
Grimbizis GF, Mikos T, Tarlatzis B2 (2014) Uterus-sparing operative treatment for adenomyosis. Fertil Steril 101(2):472–487
Strowitzki T, Marr J, Gerlinger C et al (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25:633–641
Harada M, Osuga Y, Izumi G, Takamura M, Takemura Y, Hirata T, Yoshino O, Koga K, Yano T, Taketani Y (2011) Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study. Gynecol Endocrinol 27(9):717–720
Hirata Tetsuya, Izumi Gentaro, Takamura Masashi, Saito Ako, Nakazawa Akari, Harada Miyuki, Hirota Yasushi, Koga Kaori, Fujii Tomoyuki, Osuga Yutaka (2014) Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol 30(10):726–729
Foster RH, Wilde MI (1998) Dienogest. Drugs 56:825–833
Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N (2005) Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8productionvi a nuclear factor kappaB inactivation in endometriotic stromalcells. Fertil Steril 83:1530–1535
Yamanaka A, Kimura F, Kishi Y, Takahashi K, Suginami H, Shimizu Y, Murakami T (2014) Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells. Eur J Obstet Gynecol Reprod Biol 179:170–174
Kang JL, Wang XX, Nie ML, Huang XH (2009) Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest 69:73–77
Morelli Michele, Rocca Morena Luigia, Venturella Roberta, Mocciaro Rita, Zull Fulvio (2013) Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Gynecol Endocrinol 29(4):305–308
Hudelist G, Oberwinkler KH, Singer CF et al (2009) Combination of transvaginal sonography and clinical examination for preoperative diagnosis of pelvic endometriosis. Hum Reprod 24:1018–1024
Fedele L, Bianchi S, Dorta M, Arcaini L, Zanotti F, Carinelli S (1992) Transvaginal ultrasonography in the diagnosis of diffuse adenomyosis. Fertil Steril 58:94–97
Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, Masuzaki H (2010) Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod 25(11):2878–2890
Grow DR, Filer RB (1991) Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol 78:538–539
Graser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oette LM (2000) Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest—a dose-ranging study. Maturitas 35:253–261
Irahara M, Harada T Momoeda M, Tamaki Y (2007) Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 6:223–228
Nagata C, Yanagida S, Okamoto A et al (2012) Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res 38:639–644
Napolitano M, Dolce A, Celenza G, Grandone E, Perilli MG, Siragusa S, Carta G, Orecchioni A, Marian G (2014) Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. Ann Hematol 93:557–563
Warner PE, Critchley HO, Lumsden MA et al (2004) Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224–1229
Parsanezhad M, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt E (2010) A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 93:192–198
Bazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine JM et al (2001) Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 16:2427–2433
Conflict of interest
No potential conflict of interest relevant to this article was reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fawzy, M., Mesbah, Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet 292, 1267–1271 (2015). https://doi.org/10.1007/s00404-015-3755-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-015-3755-5